Nykredit A/S’s Bio-Rad Laboratories Class A BIO Stock Holding History

Nykredit A/S’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$118K	Buy	+403	New	+$114K	﹤0.01%	1259

Other funds holding BIO

First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Nykredit A/S's BIO Position: Q2 2026 in Review

Nykredit A/S opened a new position in Bio-Rad Laboratories Class A (BIO) in Q2 2026: 403 shares worth $118K. The stake represents ﹤0.01% of the portfolio and ranks #1259 among its holdings.

304 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

Nykredit A/S held 403 shares of Bio-Rad Laboratories Class A worth $118K as of Q2 2026.
Bio-Rad Laboratories Class A was a new Nykredit A/S position in Q2 2026.
Bio-Rad Laboratories Class A made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1259 holding.
304 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.